In stage III colon cancer, a study found KRAS mutation status was not associated with the OS or RFS or DFS of patients (Ogino et al., 2009), while more recently studies found the KRAS mutation would worsen the DFS (Sperlich et al., 2018) or survival after recurrence (SAR) (Taieb et al., 2019) of patients. The gene discussed is KRAS; the disease is malignant colon neoplasm.